Disc Medicine (NASDAQ:IRON) Issues Quarterly Earnings Results

Disc Medicine (NASDAQ:IRON - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.98) EPS for the quarter, beating analysts' consensus estimates of ($1.06) by $0.08, Zacks reports.

Disc Medicine Trading Down 3.3 %

Shares of IRON traded down $1.85 during mid-day trading on Monday, reaching $54.33. The company had a trading volume of 187,309 shares, compared to its average volume of 391,513. Disc Medicine has a fifty-two week low of $25.60 and a fifty-two week high of $77.60. The firm has a fifty day simple moving average of $58.08 and a 200-day simple moving average of $55.65. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of -13.65 and a beta of 0.73.

Analysts Set New Price Targets

Several analysts have issued reports on IRON shares. HC Wainwright reaffirmed a "buy" rating and issued a $118.00 price target on shares of Disc Medicine in a report on Tuesday, January 21st. Morgan Stanley raised Disc Medicine from an "equal weight" rating to an "overweight" rating and set a $85.00 price target for the company in a research report on Tuesday, November 5th. Scotiabank boosted their target price on shares of Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a research note on Monday. TD Cowen initiated coverage on shares of Disc Medicine in a research note on Thursday. They set a "buy" rating on the stock. Finally, Stifel Nicolaus boosted their price objective on shares of Disc Medicine from $90.00 to $94.00 and gave the company a "buy" rating in a research report on Friday, January 24th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $89.10.

Remove Ads

Insider Transactions at Disc Medicine

In other Disc Medicine news, CFO Jean M. Franchi sold 3,136 shares of Disc Medicine stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total transaction of $171,162.88. Following the transaction, the chief financial officer now directly owns 69,530 shares of the company's stock, valued at $3,794,947.40. The trade was a 4.32 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO John D. Quisel sold 19,820 shares of the stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $63.14, for a total transaction of $1,251,434.80. Following the completion of the sale, the chief executive officer now directly owns 72,065 shares of the company's stock, valued at $4,550,184.10. The trade was a 21.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 74,080 shares of company stock worth $4,523,520 in the last ninety days. Insiders own 4.24% of the company's stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.